Sanofi Reports meta-analysis Data for Venetoclax in Esophageal cancer

Sanofi today announced meta-analysis results for venetoclax in patients with esophageal cancer. The study demonstrated that venetoclax demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of esophageal cancer and support the continued development of venetoclax in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.